source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…
- Bristol Myers pushes Cobenfy Alzheimer’s psychosis readout to early 2027 after enrollment delaysBristol Myers Squibb said the Phase 3 readout for its Cobenfy Alzheimer’s psychosis program will be postponed to early 2027. The company had previously expected data from the three Adept trials to…